October was a good month for the stock market. The S&P 500 rose 8% after earnings season didn't turned out to be as disastrous as investors and analysts had feared. One stock that did exceptionally well last month was DexCom (NASDAQ: DXCM) , which soared by a whopping 50%. At around $120 per share, the stock hasn't been this high since April.
Has DexCom's stock risen too sharply in value for it to still be a good buy right now, or can it continue rising and build off its recent gains?
On Oct. 27, DexCom released its third-quarter earnings results, which showed excellent growth and beat analyst expectations. After consecutive quarters of missing Wall Street estimates, the company reported adjusted earnings per share (EPS) of $0.28, which soundly exceeded analyst projections of $0.24.
For further details see:
Is It Too Late to Buy DexCom Stock?